Best Labiotech Podcasts (2025)

1
Biotech royalty deals on the rise and here to stay 51:18

Play Pause

1h ago51:18

51:18

In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx. HCRx are pioneers in royalty-based financing, with a thirty year track record in biopharma investing. Clarke has led more than 60 royalty acquisitions totaling nearly $4 billion and raised over $8 billion across various vehicles, executing more th…

1
Contraline's ADAM in the clinic: towards a new era of male contraception? 40:33

6d ago40:33

40:33

When it comes to contraception, most of the innovation in the last century has focused on providing contraceptive alternatives for women. The contraceptive pill was approved by the FDA in 1960, the first IUD approved in 1968, and the female condom in 1993. For men, however, there has been little advancement since the invention of the rubber condom …

1
Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play 44:49

13d ago44:49

44:49

Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people, and how do you move from ‘I’m interested’ to ‘I’m signing on the dotted line’? This week I talk with Gera…

1
What’s next in immunology & inflammation R&D: The trends to watch 51:25

20d ago51:25

51:25

Immunology and inflammation are hot topics in biotech and biopharma, and innovations are emerging that can change the game for patients suffering from autoimmune, gastrointestinal, and metabolic disease. For top pharma companies, identifying these innovations early is essential and, for university labs, spinouts and startups, getting their science …

1
BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year 44:54

29d ago44:54

44:54

Partnering conferences are where many deals in the biotech industry get made. With investors and top pharma companies on hand to meet with founders, learn about new science, and put money on the table for promising biotech, it’s little wonder that the biggest partnering events attract hundreds of innovators and thousands of attendees. One of the la…

1
AION Labs is building innovative biotechs with top pharma partners in Israel 42:09

1M ago42:09

42:09

How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on will be attractive to industry partners? And can AI help drive this interest and deliver these partnerships? These are questions that this week’s guest, Mati Gill, CEO of AION Labs in Israel, is perfe…

1
Navigating the biotech development journey from first steps to global scale with Lonza 50:40

1M ago50:40

50:40

Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical companies – to transform therapeutic discoveries into life-saving and life-enhancing treatments for their…

1
A Finnish biotech is making progress on Parkinson's disease with support from The Michael J. Fox Foundation 38:02

2M ago38:02

38:02

Parkinsons disease impacts some 10 million people worldwide and current approaches to treating the condition almost exclusively focus on addressing symptoms – there is, as of yet, no cure. One Finnish biotech, however, is not focused on alleviating symptoms but on modifying the course of the disease itself. Their hope is to be able to stop and even…

1
How RNAi is expanding from a therapy of choice for rare disease into treating common conditions 48:01

2M ago48:01

48:01

RNAi has changed the way that rare diseases are treated - is it about to do the same for more common conditions? Alnylam was the very first company to translate RNAi from Nobel Prize winning science into a commercially scalable platform. Founded in 2002, the company today has five different RNAi therapies on the market and a pipeline that continues…

1
Are next-generation psychedelics the way forward for addressing treatment resistant depression? 49:07

2M ago49:07

49:07

Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 trillion by 2030. One of the most common of those mental health disorders is depressive disorder, commonly called depression, with some 280 million people suffering from either mild, moderate or severe …

1
Day One DNA: How and why the UK is betting on whole genome sequencing for every newborn 49:57

2M ago49:57

49:57

The UK is preparing to change the game for healthcare - but why, how, and what will it cost? Recently the UK government announced plans to sequence the DNA of every baby born in that country. A part of the country’s 10 Year Health Plan, the program aims to identify rare genetic diseases early, prevent harms from delayed treatment and reduce future …

1
Meatly's innovative cultivated meat is already delighting pets, are humans next? 38:45

3M ago38:45

38:45

Is cultivated meat the future of pet food? And is there a place for cultivated meat on human dinner tables, too? Traditional agricultural methods are slow, require large tracts of land, significant energy and environmental inputs, and – somewhat obviously – the slaughter of hundreds of millions of animals every year. Cultivated meat – that is meat …

1
Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience 48:30

3M ago48:30

48:30

With supply chain management and optimization, risk management, and the capacity to address global markets efficiently and effectively top of mind for all growing biotechs, I'm excited to be joined by Alison Pritchard, Vice President, Business Development at Cryoport Systems, to learn more about how they support life science innovators worldwide. C…

1
Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a/C5aR signaling pathway strategy 39:24

3M ago39:24

39:24

Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous system. The demand for anti-inflammatory treatments is growing quickly and is tipped to top a quarter of a trillion dollars within the decade as cases i…

1
How OMass Therapeutics is tackling congenital adrenal hyperplasia, a rare genetic disorder 34:27

3M ago34:27

34:27

Ros Deegan is an industry leader and the CEO of OMass Therapeutics, an Oxford-based biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. OMass’s MC2 program targeting Congenital Adrenal Hyperplasia, or CAH, is set to enter the clinic this year and in our interv…

1
Persica Pharmaceuticals is treating the cause of chronic lower back pain, not just the symptoms 38:29

4M ago38:29

38:29

The World Health Organization reports that more than 600 million people suffer from lower back pain globally, making it the leading cause of disability worldwide. Chronic lower back pain – where the pain persists for more than 3 months – develops in between 5 and 10% of all lower back pain cases, with life-altering impacts for patients. And that’s …

1
Humacyte: Saving lives with lab-grown blood vessels in conflict zones 36:27

4M ago36:27

36:27

Trauma surgeons in Ukraine operating theaters saved lives and limbs thanks to the innovative lab-grown blood vessels from US biotech, Humacyte. Humacyte is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs that are designed to be universally implantable, off-the-shelf, and r…

1
Special Episode: The 2025 BIO International Convention 38:20

4M ago38:20

38:20

Much of the attention of the biotech industry has been focused on the city of Boston this week as the annual BIO International Convention hit town. BIO is the world’s largest partnering conference for the biopharma industry and thousands of innovators, out-licensors, venture capitalists, top pharma dealmakers, thought leaders and more than a few po…

1
Alex Telford on AI, drug discovery, digital twins, and the most interesting questions in biotech 46:26

4M ago46:26

46:26

What are the most interesting questions in biotech, and is it even possible to find answers to those questions? Alex Telford is the co-founder of Convoke and a biotech blogger from the San Francisco Bay Area. His blog post, 'Some questions about biotech that I find interesting' provoked conversations online as readers engaged with questions about t…

1
Corporate venture capital and biotechnology in 2025: challenges, opportunities, and threats 42:12

4M ago42:12

42:12

When biotechs start fundraising they regularly turn to the venture capital market seeking investment. The pool of VC money can be large, and part of that pool is corporate venture capital. Backed by firms keen to identify the next big thing in biotechnology, corporate VC money can be an attractive way for biotechs to raise funds privately while ben…

1
The state of biotech finance and fundraising in Q2 2025 with Baker McKenzie 39:27

5M ago39:27

39:27

Biotechnology has always been a dynamic domain, but the world of finance that provides the fuel for the fire is just as vibrant. Trying to predict where the market for biotech investment is heading is always risky but for experts like Baker McKenzie’s Roel Meers, understanding where the market is moving is where he eats. I spoke to Roel this week t…

1
How generative AI and 'Photoshop for proteins' are transforming biopharma R&D 35:00

5M ago35:00

35:00

Generative artificial intelligence (GenAI) is already changing how people research, communicate, and interact, but its biggest impacts on biotech are still to come. Cradle is a Dutch-Swiss biotech startup founded in 2021 that has developed a web-based software platform leveraging GenAI to accelerate protein design and optimization, aiding scientist…

1
Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells 33:52

5M ago33:52

33:52

There are cell therapies, gene therapies, and biologics – and then there is Immusoft. Immusoft sits at the nexus point of some of the most innovative approaches in biopharma, and their Immune System Programming platform is unique in its capacity to address the rare disease, MPS I. This week we talk with Immusoft CEO Sean Ainsworth to learn more abo…

1
Inside Flagship Pioneering's strategy: How this VC turns ideas into biotech giants 44:25

5M ago44:25

44:25

Flagship Pioneering doesn't go out to find the next big thing in biotech when investing their billions in fund capital - instead, they take a different route. Flagship Pioneering has founded more than 100 companies in the life sciences worth in total an estimated $75 billion. With a proven model for biotech startup success and a culture designed to…

1
TCR-NK: A novel cell therapy transforming cancer treatment 34:00

6M ago34:00

34:00

Are TCR-NK treatments the next big thing in cell therapies for cancer patients? As biotechs and pharma companies continue to innovate to address patient needs in oncology, T-cell receptor therapies, or TCR-Ts, are attracting significant interest and investment. There are already some promising results for TCR-Ts tackling solid tumors – but one Norw…

1
AI in biotech today, and how it will impact the industry tomorrow 39:40

6M ago39:40

39:40

AI is driving innovation across industries, including biotech, but where is its influence felt most and what opportunities for future impact are emerging? David del Bourgo is the co-founder and CEO of WhiteLab Genomics, an innovative biotech that is leveraging the power of AI to accelerate drug discovery and development from its Paris, Boston, and …

1
How nanobodies will revolutionize immunotherapy 41:13

6M ago41:13

41:13

From llamas and camels to humans worldwide. Nanobodies are enjoying success in the clinic and experts are hailing these camelid-derived biologics as one of the next big things in immunotherapy. Kristian Reich is co-founder and CSO of MoonLake Immunotherapeutics. After a long and distinguished career as a clinician and researcher, Kristian helped to…

1
Meeting the global demand for cell therapies: scaling with smart manufacturing 39:38

7M ago39:38

39:38

Cell therapies are at the cutting edge of personalized medicine but as demand for these therapies grows, how will the industry scale manufacturing to meet patient needs? Fabian Gerlinghaus is co-founder and CEO of Cellares. He and his team have developed the Cell Shuttle, an advanced cell manufacturing technology that is already demonstrating the p…

1
Treating spinal cord injuries with stem cells 33:48

7M ago33:48

33:48

Spinal cord injuries impact millions of people worldwide and, unlike many chronic injuries, they usually arrive with no forewarning, impacting the young and old alike. Brian Culley is CEO of Lineage Cell Therapeutics and his company is now in the clinic with a stem cell therapy for spinal cord injuries. Learn why stem cells could be promising for t…

1
Are mitochondrial therapeutics about to go mainstream? 37:47

7M ago37:47

37:47

Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough? Klaus Dugi is CEO of Vandria, a biotech that develops mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. He joins 'Beyond Biotech' to talk cell mitophagy, biotech agility, and…

1
Fighting Alzheimer's with innovative stem cell therapies 41:51

7M ago41:51

41:51

Regeneration Biomedical has developed a new technique to address neurodegenerative diseases like Alzheimer's using stem cell therapy. Dr. Christopher Duma, has long been an innovator in neurosurgery using a gamma knife radiosurgery to treat glioblastoma. Now with Regeneration Biomedical, Duma is taking on neurodegenerative diseases with a first-in-…

1
[Rebroadcast] How AI immune system mapping can boost drug discovery 28:53

7M ago28:53

28:53

We’re taking a short break this week and, while we’re away, we invite you to enjoy one of our favorite episodes. We will return with a brand-new episode next week! Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering …

1
The TCR-T cell therapies of tomorrow 26:42

8M ago26:42

26:42

Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1. The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a leading Swedish industrialist, who became co-founder, and provided the initial financing. The company has raised more …

1
Can RNA drugs solve the obesity epidemic? 29:56

8M ago29:56

29:56

Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment. Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets underlying biological pathways to promote sustainable weight loss. By enhancing energy expenditure through white-to-br…

1
Reversing cancer mechanisms to fight back against solid tumors 21:24

8M ago21:24

21:24

CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications. Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance. Neutralizing GDF-15 with …

1
Targeting the dark genome to develop new therapies to fight obesity 32:32

8M ago32:32

32:32

In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity. The company’s lead candidate, HTX-001, is making progress towards the clinic in cardiomyopathy. CEO Samir is one of the first researchers to publish on lncRNA – which is also k…

1
Can Tumor Activated Therapy kill solid tumors? 31:22

9M ago31:22

31:22

Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy. By targeting specific proteins common in all solid tumor micro-environments, Seekyo scientists think this can induce self-destruction of the tumor itself. Seekyo’s lead therapy, SKY01, can only be activated withi…

1
J.P. Morgan Annual Healthcare Conference 2025: trends and highlights you may have missed 19:57

9M ago19:57

19:57

This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently. While there weren’t necessarily many financial blockbusters, there were plenty of announcements and discussions on everything from artificial intelligence to the rising influence of Chinese companie…

1
Venture capital co-creation: The next big thing in biotech investment? 37:22

9M ago37:22

37:22

Jessica Owens and Iana Dimkova are co-founders of Initiate Ventures—a female-led venture capital firm and studio that launched recently with a $45 million debut fund. Initiate Ventures is shaking up the traditional venture capital model by blending investments in healthcare, life sciences, and technology with a company creation platform. The compan…

1
Developing non-opioid pain drugs 33:01

9M ago33:01

33:01

Brixton Biosciences, a clinical-stage life sciences company spun out from Massachusetts General Brigham, has been awarded $2m from the NIH HEAL Initiative to support the development of non-opioid, injectable pain relief solutions. As part of the NIH's efforts to tackle the U.S. opioid crisis, the funding will advance research into safer, drug-free …

1
[Rebroadcast] The power of natural killer cells 28:59

10M ago28:59

28:59

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season! On this podcast, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural …

1
Looking at 2025 biotech trends with SoftBank Vision Fund 39:04

10M ago39:04

39:04

Our guest on the podcast this week is John Cassidy, director of life sciences and healthtech investments at SoftBank Vision Fund. Softbank Vision Fund is the world’s largest technology-focused investment fund, with $166bn assets under management, and a portfolio of more than 250 companies. In the discussion, we cover investment trends within life s…

1
Finding new treatments for peanut allergy 31:06

10M ago31:06

31:06

There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens. IgGenix, a clinical-stage immunology biotechnology company, recently announced the first patient dosed in its phase 1 trial evaluating IGNX001, a novel monoclo…

1
Cracking the code of biotech valuations 37:43

10M ago37:43

37:43

ambiom is a life science commercial-advisory business development company based in the Slovakian capital of Bratislava. The company helps its corporate clients with their product strategy, in- and out-licensing efforts, including asset valuation (NPV, rNPV), M&A scouting, complex due diligence and dealmaking. ambiom also provides input on regulator…

1
Can biotech beat mosquito-borne diseases? 35:59

11M ago35:59

35:59

Biological control company Oxitec recently launched Sparks, a new platform designed to rapidly scale Wolbachia replacement technology to take on dengue fever. Backed by a multi-million-dollar investment from the Gates Foundation, Sparks adds to Oxitec’s Aedes aegypti technology, called Friendly, which is taking on dengue fever in Brazil. With mosqu…

1
Could antigen modulation address autoimmune diseases? 24:04

11M ago24:04

24:04

Immunology is a key area in biotech and biopharma, both in terms of R&D and sales. However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle. To have an immunological effect, you must activate the body’s T cells, which cells requires a chain of three key signals. The first is antigen rec…

1
Beyond profits: The Bill & Melinda Gates MRI's mission to combat neglected diseases 38:10

11M ago38:10

38:10

The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoclonal antibodies to address substantial global health concerns, for which investment incentives are limited, including malaria, tuberculosis, diarrheal…

1
How to succeed as a woman in biotech 34:12

11M ago34:12

34:12

This week, we are taking a look at an important subject, and that is women working as CEOs, or other senior roles, in the biotech space. Kate Yen is the CEO of oncology biotech Auron Therapeutics, and she has spent her entire career in science. Auron is working on the next generation of targeted cancer therapies by identifying and inhibiting the on…

1
The immunometabolism landscape 30:13

12M ago30:13

30:13

Sitryx Therapeutics is a private UK biopharma company founded in 2018. It is a leader in the field of immunometabolism, an area of immunology that looks to rebalance the immune system to achieve sustained disease remission in autoimmune and inflammatory diseases. Sitryx already has big pharma validation following a deal with Eli Lilly in 2020 worth…

1
Biotech beyond earth: The future of medicine in space 39:01

12M ago39:01

39:01

LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease. Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief operating officer. After reading an article about how space-travel is especially damaging to the kidneys, they applied for a place on the inaugural N…